Stifel Financial Corp Sells 6,893 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Stifel Financial Corp lowered its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 20.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 26,723 shares of the company’s stock after selling 6,893 shares during the quarter. Stifel Financial Corp’s holdings in IDEXX Laboratories were worth $11,048,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Geode Capital Management LLC increased its stake in shares of IDEXX Laboratories by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company’s stock valued at $948,279,000 after buying an additional 37,734 shares during the period. Franklin Resources Inc. lifted its position in IDEXX Laboratories by 2.5% during the 3rd quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company’s stock valued at $675,259,000 after purchasing an additional 34,305 shares during the period. Invesco Ltd. grew its position in shares of IDEXX Laboratories by 6.8% during the 4th quarter. Invesco Ltd. now owns 1,160,988 shares of the company’s stock worth $479,999,000 after buying an additional 74,324 shares during the period. Norges Bank bought a new stake in shares of IDEXX Laboratories during the fourth quarter worth approximately $412,258,000. Finally, American Century Companies Inc. lifted its holdings in IDEXX Laboratories by 30.9% in the fourth quarter. American Century Companies Inc. now owns 809,814 shares of the company’s stock valued at $334,810,000 after buying an additional 191,385 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Up 2.3 %

NASDAQ:IDXX opened at $411.72 on Friday. The firm has a market capitalization of $33.37 billion, a price-to-earnings ratio of 38.59, a price-to-earnings-growth ratio of 3.41 and a beta of 1.50. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $548.88. The stock’s 50 day moving average price is $422.37 and its two-hundred day moving average price is $430.84.

Insider Activity

In related news, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. The trade was a 54.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. 0.98% of the stock is owned by insiders.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, April 12th. Barclays boosted their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Piper Sandler lifted their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Stifel Nicolaus dropped their target price on shares of IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating on the stock in a report on Monday, April 14th. Finally, Morgan Stanley reduced their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $523.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.